Medicine: Managing aortic stenosis, Warning about a gout drug

Podcast
News from the World of Medicine
  • 2020 08, Medicine, Managing aortic stenosis, Warning about a gout drug
    29:25
audio
Medicine: Back pain; Atrial fibrillation
audio
Medicine: How to measure pain?
audio
Medicine: A “change” in the treatment of gout
audio
Medicine: Invasive or conservative therapy for coronary artery disease?
audio
Medicine: Why are we sceptical about the AstraZeneca vaccine
audio
Medicine: Vaccination against COVID-19
audio
Medicine: Follow-up colonoscopy for small adenomas, 25% of antibiotics inappropriate
audio
Medicine: The new cholesterol guideline, No link between MMR vaccine and autism
audio
Medicine: Treatment of atrial fibrillation, Small amounts of alcohol cause cancer

The first medical topic today:
Three clinical studies published in 2019 led to the conclusion either open-heart surgery or minimally invasive heart surgery will be used more often in the future in patients with aortic stenosis. The minimally invasive heart surgery for aortic stenosis is transcatheter aortic valve replacement. The three clinical studies published in 2019 showed that either open-heart surgery or minimally invasive heart surgery (that is, as mentioned, transcatheter aortic valve replacement for the patients with aortic stenosis), can now expand also to lower-risk patients.
The second medical news today:
A warning has been issued about a gout drug. The U.S. Food & Drug Administration (the FDA) has mandated that the drug febuxostat for patients with gout carries a boxed warning, I repeat, a boxed warning, in other words, a highly visible warning, to alert doctors and patients to the increased risk of death due to cardiovascular causes as a side effect of febuxostat.

Documents

2020 08, Medicine, Text, Managing aortic stenosis, Warning about a gout drug, PDF, 158.7 kB Download

Leave a Comment